Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression

Javad Habibi,1,4* Vincent G. DeMarco,1,2# Lixin Ma,3 Lakshmi Pulakat,1,4,5 William E. Rainey,6 Adam T. Whaley-Connell,1,4,5 and James R. Sowers1,2,4,5

Departments of 1Internal Medicine, 2Medical Pharmacology and Physiology, and 3Radiology, School of Medicine, and 4Diabetes and Cardiovascular Laboratory, University of Missouri, Columbia; 5Harry S. Truman Veterans Affairs Medical Center, Columbia, Missouri; and 6Medical College of Georgia, Augusta, Georgia

Submitted 5 October 2010; accepted in final form 6 January 2011

Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, Sowers JR. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 300: H1484–H1491, 2011. First published January 14, 2011; doi:10.1152/ajpheart.01000.2010.—There is emerging evidence that mineralocorticoid receptor blockade improves diastolic function independent of changes in blood pressure through actions on myocardial oxidative stress and fibrosis. We used young transgenic (mRen2)27 [TG(mRen2)27] rats with increases in both tissue ANG II and circulating aldosterone, which manifests age-related increases in hypertension and cardiac dysfunction. Male TG(mRen2)27 and age-matched Sprague-Dawley rats were treated with either a low dose (−1 mg·kg−1·day−1) or a vasodilatory, conventional dose (−30 mg·kg−1·day−1) of spironolactone or placebo for 3 wk. TG(mRen2)27 rats displayed increases in systolic blood pressure and plasma aldosterone levels as well as impairments in left ventricular diastolic relaxation without changes in systolic function on cine MRI. TG(mRen2)27 hearts also displayed hypertrophy (left ventricular weight, cardiomyocyte hypertrophy, and septal wall thickness) as well as fibrosis (interstitial and perivascular). There were increases in oxidative stress in TG(mRen2)27 hearts, as evidenced by increases in NADPH oxidase activity and subunits as well as ROS formation. Low-dose spironolactone had no effect on systolic blood pressure but improved diastolic dysfunction comparable to a conventional dose. Both doses of spironolactone caused comparable reductions in ROS/3-nitrotyrosine immunostaining and perivascular and interstitial fibrosis. These data support the notion mineralocorticoid receptor blockade improves diastolic dysfunction through improvements in oxidative stress and fibrosis independent of changes in systolic blood pressure.

aldosterone; fibrosis; renin-angiotensin-aldosterone system

REMODELING OF CARDIAC TISSUE in hypertension is characterized by myocyte hypertrophy and interstitial fibrosis, which facilitate the development of left ventricular (LV) diastolic dysfunction (27, 41). In this context, increases in aldosterone levels are associated with increased heart failure mortality (9, 22), and blockade of mineralocorticoid receptors (MRs) improves morbidity and mortality (22, 25, 26), including those with preserved ejection fraction (EF), e.g., diastolic dysfunction (15, 18). Both cardiac myocytes and fibroblasts express MRs with a high affinity for aldosterone (17, 32, 38). However, the development of interstitial fibrosis and diastolic dysfunction by aldosterone actions on the MR may occur when the renin-angiotensin-aldosterone system (RAAS) is inappropriately activated relative to salt intake, i.e., in the absence of salt deprivation (30, 32).

Inappropriate activation of the RAAS through aldosterone actions on the MR have been shown to promote the development of diastolic dysfunction through putative nongenomic actions including the generation of oxidative stress in models of chronic pressure overload (18, 22, 38). Oxidative stress is known to impair metabolic signaling pathways that regulate cardiac remodeling, LV hypertrophy (LVH), and diastolic dysfunction through interstitial fibrosis (16). Experimental studies (14, 21, 36) have shown beneficial effects of MR antagonist therapy on myocardial fibrosis independent of blood pressure effects. It has been suggested that these blood pressure-independent, antifibrotic effects of MR antagonists are mediated, in part, through reductions in myocardial oxidative stress (14, 21, 36, 43).

Cardiac tissue remodeling manifests early as impairments in diastolic relaxation time (e.g., diastolic dysfunction) characterized by stiffness and is characteristically seen in conditions of pressure overload and inappropriate activation of the RAAS (27, 37, 41). Thus, diastolic dysfunction is promoted by hemodynamic and hormonal influences that promote hypertrophy and cardiac fibrosis. Thereby, we hypothesized that blockade of the MR would improve diastolic dysfunction through improvements in oxidative stress and interstitial fibrosis independently of changes in systolic blood pressure (SBP) in a rodent model of RAAS activation, the transgenic (mRen2)27 (R2) rat. This hypertensive, insulin-resistant model displays increased tissue ANG II and circulating aldosterone and manifest increases in tissue oxidative stress and interstitial fibrosis (36, 43, 44). To evaluate the blood pressure-independent effects of MR antagonism on diastolic function, we compared a low, non-pressure-lowering dose of spironolactone (Sp) (36, 43) with that of a conventional blood pressure-lowering dose (15, 21).

MATERIALS AND METHODS

Animals and Treatments

All animal procedures were approved by the University of Missouri Animal Care and Use Committee and housed in accordance with National Institutes of Health guidelines. Male R2 rats (5–6 wk of age) and age-matched Sprague-Dawley (SD) rats were randomly assigned to untreated groups (R2C and SDC, respectively) or treated with Sp at either a low dose or a conventional dose. R2 and SD rats were implanted with a timed-release Sp pellet designed to deliver either 5,

* J. Habibi and V. G. DeMarco contributed equally to this work.

Address for reprint requests and other correspondence: J. R. Sowers, Univ. of Missouri-Columbia, D109 Diabetes Center HSC, One Hospital Dr., Columbia, MO 65212 (e-mail: sowersj@health.missouri.edu).
In Vivo Cine MRI

Noninvasive MRI scans were performed within 72 h of the end of the treatment period using a Varian 7-T horizontal-bore MRI (Varian, Palo Alto, CA) equipped with a 60-mm birdcage radiofrequency coil as previously described (36, 44, 47). All values are expressed as means ± SE. Statistical analyses were performed using a t-test for aldosterone measures and two-way ANOVA with Tukey’s post hoc test for all other outcomes (SigmaStat 3.1, Systat Software, Chicago, IL).

RESULTS

Sp Effects on Experimental Parameters

There were increases in circulating aldosterone in R2C rats compared with SDC rats (936 ± 198 vs. 501 ± 122 pg/ml, \( P < 0.05 \)), and the higher plasma aldosterone level in R2C rats was associated with increased SBP compared with SDC rats (\( P < 0.05 \); Table 1). These data confirm previous reports demonstrating hyperaldosteronemia in the hypertensive Ren2 rat. Conventional-dose Sp but not low-dose Sp reduced SBP (Table 1 and Fig. 1).

The presence of insulin resistance is an important predictor of diastolic dysfunction in models of pressure overload and hypertension (19, 20). While there was a trend in the homeostatic model assessment of insulin resistance data suggesting

Plasma Aldosterone

Rat blood samples were collected from the lumen of the LV at autopsy after experimental treatment and stored at \(-20^\circ\text{C}\). The plasma aldosterone content was determined using a radioimmunoassay from Siemens (Los Angeles, CA) using the manufacturer’s protocol. Radioactivity was read using a multicrystal \( \gamma \)-counter (Gamma-C 12 DPC, Berthold, Germany).

LVH

At autopsy, the LV plus septum (LV + S) was dissected free of the right ventricle, atria, and great vessels. (LV + S) normalized to body weight is a commonly used index of LVH in nonobese rodent models.

Light Microscopic Analysis for Cardiomyocyte Hypertrophy and Myocardial Fibrosis

Tissue samples were excised from similar sections of the lateral wall of the LV and processed for light microscopy. Samples from five rats from each of the four treatment groups were analyzed as follows. Paraffin sections (5 \( \mu \)m) were deparaffinized, rehydrated, and stained with Verhoeff-Van Gieson (VVG) stain, which stains collagen type III and elastin fibers pink, to evaluate interstitial and perivascular fibrosis, as previously described (44). Ten nonoverlapping images (1,392 × 1,040 pixels) were captured and analyzed by an individual blinded to the animal and treatment group. Perivascular fibrosis was measured as the percent area of the vascular wall of coronary arterioles, including the intima, media, and adventitia, presenting fibrosis on VVG staining. To quantify only collagen staining in either the periartrial or interstitial areas, all other colors were filtered out with the aid of MetaVue software. The area within each of the 10 images was quantified by MetaVue, and an average value was generated for each rat and expressed as arbitrary units. The accuracy of this technique has been confirmed by immunostaining of the myocardium with antibodies to collagen. To evaluate cardiomyocyte hypertrophy, digital images were captured on cardiomyocytes in cross-section, and the cross-sectional area was determined with the aid of image-analysis software. To quantify cardiomyocyte size, ~20 cells from 2 separate sites were measured per sample, and only cardiomyocytes with a well-defined cellular membrane and visible nucleus were measured. The average size of all measured cardiomyocytes within a sample was determined and expressed in units of cross-sectional area (in \( \mu \)m\(^2\)).

Statistical Analysis

All values are expressed as means ± SE. Statistical analyses were performed using a t-test for aldosterone measures and two-way ANOVA with Tukey’s post hoc test for all other outcomes (SigmaStat 3.1, Systat Software, Chicago, IL).
Table 1. Experimental parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ANOVA</th>
<th>SDC</th>
<th>R2C</th>
<th>R2 LSp</th>
<th>R2 Sp</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td></td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Age, wk</td>
<td>0.041</td>
<td>8.7 ± 0.3</td>
<td>8.2 ± 0.2</td>
<td>8.8 ± 0.4</td>
<td>9 ± 0.3</td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>&lt;0.001</td>
<td>126 ± 4</td>
<td>145 ± 2*</td>
<td>154 ± 6*</td>
<td>150 ± 2*</td>
</tr>
<tr>
<td>Initial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final</td>
<td>&lt;0.001</td>
<td>140 ± 4</td>
<td>190 ± 3*</td>
<td>199 ± 7*</td>
<td>163 ± 7*†</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>ND</td>
<td>103 ± 19</td>
<td>109 ± 2</td>
<td>138 ± 13</td>
<td>123 ± 4</td>
</tr>
<tr>
<td>Initial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final</td>
<td>ND</td>
<td>256 ± 10</td>
<td>255 ± 7</td>
<td>267 ± 11</td>
<td>263 ± 6</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>ND</td>
<td>0.06 ± 0.02</td>
<td>0.15 ± 0.06</td>
<td>0.08 ± 0.01</td>
<td>0.02 ± 0.0</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, sample size. Rats were divided into the following groups: Sprague-Dawley control (SDC), transgenic (mRen2:27 (R2) control (R2C), R2 rats treated with low-dose spironolactone (R2 LSp), and R2 rats treated with conventional-dose spironolactone (R2 Sp). Systolic blood pressure (SBP) and body weight were measured immediately before treatment (initial) and at the end of the treatment period (final). ND indicates that no differences were observed by ANOVA. *P < 0.05 vs. the SDC group; †P < 0.05 vs. the R2 LSp group.

Sp Improves LV Diastolic Function

There were no changes in heart rate, LV volumes (EDV and ESV), or systolic indexes (cardiac index and EF) in either strain or with treatment (Table 2). However, there was observable diastolic dysfunction determined by an increased LV diastolic relaxation time and a reduced initial filling rate in R2 rats compared with SDC rats (P < 0.05; Table 2 and Fig. 2). Despite the absence of a reduction in SBP, low-dose Sp treatment in R2 rats resulted in improved diastolic function, characterized by an increased initial filling rate and a reduced diastolic relaxation time compared with R2C rats (P < 0.05; Table 2 and Fig. 2). The improvement in diastolic dysfunction with the blood pressure-lowering conventional dose of Sp, like the low dose of Sp, resulted in an increased initial filling rate (P < 0.05); however, the reduction in diastolic relaxation time did not reach statistical significance (Table 2 and Fig. 2).

Sp Improves LV Oxidative Stress

Antagonism of the MR is thought to improve diastolic dysfunction through improvements in oxidant stress through nongenomic actions (17, 19, 20). In this regard, the increases in the level of ROS, measured by chemiluminescence, or 3-nitrotyrosine, measured by immunostaining, in the LV of R2C rats compared with SDC rats were improved with both doses of Sp (Fig. 3, A–C).

Oxidative stress in this model is driven by the enzyme complex NADPH oxidase (27). As previously reported (1, 33), NADPH oxidase activity was elevated in R2C rats compared with SDC rats (Fig. 4A). There were elevations in NADPH oxidase subunits (NADPH oxidase 2 and Rac1) in R2C rats compared with SDC rats (Fig. 4, A and B). Interestingly, only low-dose Sp improved NADPH oxidase activity but not conventional dose, whereas both doses of Sp improved the level of subunits.

Sp Does Not Improve Measures of Hypertrophy

Increases in LV mass are inversely associated with diastolic relaxation times (8). Our data showing an increased relaxation time and a decreased initial filling rate in R2C rats (Fig. 2) and increases in markers of hypertrophy in R2C rats compared with SDC rats, including septal wall thickness, LV weight, and myocardial size, is consistent with this notion (P < 0.05; Fig. 5). On the other hand, both low and conventional doses of Sp did not improve markers of hypertrophy in R2 rats, yet improved diastolic function.

Sp Improves Fibrosis

The development of interstitial fibrosis leads to progressive stiffening of the ventricular wall, which significantly contributes to diastolic dysfunction. There were increases in interstitial fibrosis and perivascular fibrosis in R2C rats compared with SDC rats (Fig. 6, A and B, respectively), and both doses of Sp normalized the level of fibrosis in R2 rats.

DISCUSSION

The results from the present investigation suggest that diastolic dysfunction occurs in conjunction with elevated plasma aldosterone levels and increased cardiac measures of oxidative stress, hypertrophy, and fibrosis in young transgenic R2 rats. Furthermore, antagonism of the MR with a low dose of Sp improved diastolic dysfunction and oxidative stress/fibrosis without reductions in SBP in these transgenic animals compared with conventional-dose Sp treatment. Finally, our finding that both doses of Sp had no impact on measures of hypertrophy but did have a comparable impact on myocardial fibrosis suggests the early LV relaxation abnormalities mediated through MR signaling are predominantly due to fibrotic rather than hypertrophic or pressure-dependent changes. These data are the first in vivo experiments using a RAAS-dependent model that support a blood pressure-independent effect of MR signaling in mediating diastolic dysfunction in association with increases in NADPH oxidase activity/ROS and the accompanying interstitial and perivascular fibrosis.

Our finding that antagonism of the MR with a low dose of Sp reduced the diastolic relaxation time and increased the initial filling rate characteristic of diastolic dysfunction without changes in SBP in the transgenic R2 rat extend findings from other laboratories demonstrating improvement in diastolic...
function with MR blockade independently of effects on blood pressure (15, 17, 18). Although previous work on blood pressure-independent effects of MR antagonism and diastolic function have supported an essential role for salt and/or nephrectomy in promoting MR-dependent cardiac fibrosis and diastolic dysfunction (2, 15, 17, 18, 29, 31, 38), this is the first such study in a RAAS-dependent model. Because we began treatment before the onset of diastolic dysfunction, our data further suggest that low-dose Sp treatment is effective at preventing the development of diastolic dysfunction through improvements in myocardial fibrosis and oxidant stress in young transgenic rats.

Aldosterone actions on the MR have been demonstrated in cardiomyocytes and fibroblasts, the two primary cell types that contribute to hypertrophy and fibrosis in the development of diastolic dysfunction (14, 15, 17, 18, 22, 38). The putative mechanisms underlying the beneficial effects of MR blockade on diastolic dysfunction include reductions in LV interstitial fibrosis and LVH (15, 17, 18). In this context, the LV of transgenic R2 rats exhibited perivascular and interstitial fibrosis as well as increases in septal wall thickness, LV weight, and myocyte size.

The improvements in fibrosis observed with both doses of Sp treatment are consistent with previous literature showing that MRs are present in both cardiomyocytes and fibroblasts (38). The development of LV fibrosis is derived from an imbalance in the synthesis and degradation of the extracellular matrix, which is predominantly composed of collagens (types I and III). The myocardial and pericoronary fibroblasts that synthesize these collagens have been demonstrated to have MRs (3, 41). These findings corroborate our findings of fibrosis, both interstitial and perivascular, in the transgenic R2 rat that was improved with both doses of Sp.

Our findings showing improvements in fibrosis but not measures of hypertrophy with Sp treatment suggest that conditions that cause fibroblasts to abnormally synthesize collagen can be separated from the pathophysiological conditions activating cardiomyocyte hypertrophy. Indeed, MR-dependent fibrosis can occur in the both hypertrophied LV in which workload is increased as well as in the nonhypertrophied LV

### Table 2. Systolic and diastolic indexes by MRI

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SDC</th>
<th>R2C</th>
<th>R2 LSp</th>
<th>R2 Sp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at MRI, wk old</td>
<td>ND</td>
<td>8.3 ± 0.3</td>
<td>8.9 ± 0.3</td>
<td>7.9 ± 0.4</td>
</tr>
<tr>
<td>Heart rate and cardiac volumes</td>
<td>ND</td>
<td>387 ± 18</td>
<td>364 ± 17</td>
<td>396 ± 12</td>
</tr>
<tr>
<td>End-diastolic volume, µl</td>
<td>ND</td>
<td>448 ± 32</td>
<td>537 ± 40</td>
<td>427 ± 28</td>
</tr>
<tr>
<td>Systolic indexes</td>
<td>ND</td>
<td>128 ± 11</td>
<td>177 ± 19</td>
<td>145 ± 18</td>
</tr>
<tr>
<td>Cardiac index, ml·min⁻¹·g body wt⁻¹</td>
<td>ND</td>
<td>0.51 ± 0.05</td>
<td>0.49 ± 0.04</td>
<td>0.42 ± 0.02</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>ND</td>
<td>71 ± 3</td>
<td>67 ± 2</td>
<td>67 ± 2</td>
</tr>
<tr>
<td>Diastolic relaxation time, ms</td>
<td>0.001</td>
<td>19.4 ± 3.4*</td>
<td>39.9 ± 2.9</td>
<td>23.3 ± 3.9*</td>
</tr>
<tr>
<td>Peak filling rate, µl/s</td>
<td>ND</td>
<td>8.18 ± 0.46</td>
<td>8.27 ± 1.03</td>
<td>6.94 ± 0.44</td>
</tr>
<tr>
<td>Initial filling rate, µl/s</td>
<td>0.001</td>
<td>6.34 ± 0.61*</td>
<td>2.87 ± 0.54</td>
<td>5.24 ± 0.49*</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, sample size. ND indicates that no differences were observed in the ANOVA main effect. *P < 0.05 vs. the R2C group.

Fig. 2. A: typical cine MRI of SDC (top), R2C (middle), and R2 Sp rats after SP treatment (bottom). A total of 16 cine MRI frames were recorded in 1 entire cardiac cycle for each rat. The frames shown here are frames 7, 10, and 16, representing end-systolic, early diastolic, and end-diastolic phases, respectively. B–E: indexes of diastolic (B and C) and systolic (D and E) function derived from the analysis of cine MRI images. *P < 0.05 vs. R2C rats.
with a normal workload (1). This suggests that despite the presence of the MR in both cardiomyocytes and fibroblasts, the pathways that regulate the expansion of fibrous tissue are distinct from that of from myocyte growth. The hypertrophic activity of cardiomyocytes may be regulated by numerous interacting factors, including hemodynamic (ventricular overload and high coronary perfusion pressure) as well as humoral (ANG II as well as aldosterone) factors (27, 33, 41). In our model, the RAAS is activated by elevations in tissue ANG II as well as circulating aldosterone, and results from our previous studies (6, 44, 45) supports that blockade of the ANG II type 1 receptor (AT1R) improves measures of hypertrophy. Therefore, our findings that Sp treatment improves fibrosis but not hypertrophy is not entirely surprising and suggest that tissue ANG II may have a more predominant effect on hypertrophic responses in this model than aldosterone actions on the MR.

In this vein, the observed myocyte hypertrophy and interstitial fibrosis is consistent with the well-delineated effects of both ANG II and aldosterone (4, 5, 7, 10, 13, 28, 46). In addition to direct effects of mineralocorticoids in the heart, an interaction with ANG II is important in the pathogenesis of cardiac fibrosis (1, 3, 33, 42). Indeed, AT1R expression and protein levels are increased in the LV of aldosterone-treated rats (4, 10, 13). Previous work from several laboratories (4, 10, 13, 24, 39, 46) has suggested that MR activation potentiates the cardiac fibrotic effects of AT1R signaling by enhancing oxidative stress induced by ANG II. Indeed, it is well documented that pressure overload-induced heart failure enhances oxidative stress, in part through the activation of tissue AT1Rs and MRs (3, 14–16, 18, 21, 36, 41, 42). Additionally, there is substantial evidence that oxidative stress, in turn, promotes hypertrophic and proinflammatory/profibrotic changes in the myocardium (2, 15, 17, 18, 29, 30, 32, 38). However, the observation that MR blockade attenuated interstitial and perilarterial fibrosis and corrected diastolic dysfunction without effects on myocyte hypertrophy underscores the seminal role of MR in promoting diastolic dysfunction through increased fibrosis and myocardial stiffness.

The balance between ROS generation and elimination plays a pivotal role in maintaining normal cardiac function, and studies (16, 18, 39) support that excessive myocardial ROS contribute to impairments in cardiac function. There is an emerging body of evidence that ANG II and aldosterone potentiate each other’s action in stimulating myocardial

![Fig. 3. Markers of oxidative stress in cardiac tissue from control and Sp-treated SD and R2 rats. A: bar graph showing chemiluminescence-derived measures of total ROS formation. B: representative images (top) of 3-nitrotryosine (3-NTS) content, a marker for peroxynitrite formation, with average grayscale intensities (bottom). *P < 0.05 vs. R2C rats.](image)

![Fig. 4. Measures of NADPH oxidase. A: bar graph showing means ± SE values of total NADPH oxidase enzyme activity in cardiac tissue. B: representative confocal images (top) of NADPH oxidase subunits [NADPH oxidase 2 (Nox2) and Rac1] with measures of average grayscale intensities (bottom). *P < 0.05 vs. R2C rats.](image)
NADPH oxidase activity (4, 10, 13). We (4, 10, 13, 44, 45, 47) have previously reported that the primary source of ROS in R2 rats is from increased NADPH oxidase activity rather than from mitochondrial sources. Data from this investigation are consistent with other reports that ANG II and aldosterone activation of NADPH oxidase occurs through the phosphorylation and activation of p47<sub>phox</sub> and Rac1 (10, 13, 43) as well as c-Src-dependent mechanisms (4). Here, we demonstrate that treatment with a subdepressor dose of Sp resulted in reductions in NADPH oxidase activity and subunits independently of changes in blood pressure. The intermediate effect on reductions in NADPH oxidase activity observed with conventional-dose Sp may be due to the antiandrogenic properties that this compound has relative to more specific blockade of the MR with eplerenone (11, 34). Data have suggested that testosterone deficiency may have a specific effect on increasing NADPH oxidase activity that is antagonized by Sp but not eplerenone (34). Further data have suggested that Sp promotes pathways that regulate apoptosis by increasing JNK/ERK signaling and caspase activation under conditions of testosterone deficiency (11, 34).

Our finding that low-dose Sp treatment ameliorated NADPH oxidase-induced generation of ROS is important in that increases in ventricular load and mechanical strain have also

---

**Fig. 5.** Markers of cardiac tissue hypertrophy for control and Sp-treated R2 rats. A and B: bar graphs showing increased septal wall thickness via cine MRI (A) and left ventricle + septum weight normalized to body weight [(LV + S)/BW; B] in R2C, R2 LSp, and R2 Sp rats compared with SDC rats. C: representative light micrographs of cardiomyocytes in cross section. D: bar graph showing average cardiomyocyte size expressed as cross-sectional area (in μm²). *P < 0.05 for paired comparisons.

---

**Fig. 6.** Markers of fibrosis for control and Sp-treated R2 rats. A and B: representative light micrographs (top) showing collagen fiber staining (pink) upon Verhoeff-van Gieson staining in the interstitium (A) and adventitia (B) surrounding coronary arterioles with bar graphs of relative degrees of fibrosis (bottom). *P < 0.05 vs. R2C rats.
been shown to activate NADPH oxidase and contribute to cardiac structural and functional remodeling (12, 40, 41). This provides further credence that antagonism of the MR specifically improved diastolic function through improvements in oxidative stress and fibrosis.

In conclusion, early heart failure with preserved EF is estimated to comprise 50% of all heart failure disease, and the best therapeutic strategy to prevent diastolic heart disease remains controversial (23, 27, 35, 41). Hypertension, obesity, and aging are risk factors for diastolic heart disease (23, 27, 35), but the precise mechanisms that transition the heart from normal to diastolic dysfunction remain unclear. To this point, elevated aldosterone levels are associated with increased mortality in patients with hypertension and diastolic heart disease (9, 36). The observations in this study in rats with elevated plasma aldosterone, as well as other studies (13, 15, 17, 18), suggest that MR antagonism prevents myocardial fibrosis and the development of diastolic heart disease independently of hemodynamic factors. Collectively, studies have suggested that mineralocorticoids cause extracellular matrix deposition by the transcription of collagen genes and by augmenting the effects of ANG II on the transcription of these genes (1, 3, 33, 42). However, a recent report (18) has indicated that mineralocorticoids, acting through nongenomic mechanisms, promote the transition to myocardial fibrosis and diastolic heart disease in a hypertensive rodent model. The results of the present investigation suggest that increased NADPH oxidase activity and resulting increases in oxidative stress is a key mechanism by which this MR activation promotes myocardial fibrosis and associated diastolic dysfunction.

Thus, our investigation presents novel information that elucidates a potential mechanism whereby aldosterone actions on the MR and the generation of oxidative stress contribute to cardiac fibrosis and diastolic dysfunction independently of changes in blood pressure. The efficacy of Sp treatment demonstrated in this study translates to a clinically relevant therapeutic agent as a strategy for an emerging dilemma (e.g., diastolic dysfunction) in the clinical care of the cardiovascular patient.

ACKNOWLEDGMENTS
The authors acknowledge the technical contributions of Rebecca Schneider, Nathan Rehmer, and Mona Garro as well as students Safwan Hyder and Bennett Krueger. The authors thank Brenda Hunter for assistance in preparing the manuscript.

GRANTS
This work was supported by National Heart, Lung, and Blood Institute Grant R01-HL-73101-01A1, by Veterans Affairs Merit System Grants 0018 (to J. R. Sowers) and CDA-2 (to A. T. Whaley-Connell), and by the University of Missouri Research Board (to A. T. Whaley-Connell).

DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).

REFERENCES
No conflicts of interest, financial or otherwise, are declared by the author(s).


